Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients: A Taiwan Population-Based Study

Huey En Tzeng, Cheng Li Lin, Chun Hao Tsai, Chih Hsin Tang, Wen Li Hwang, Ya Wen Cheng, Fung Chang Sung, Chi Jung Chung

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Studies involving second malignancies in patients with multiple myeloma are limited for the Asian population. Using data from population-based insurance claims, we assessed the risk of developing secondary malignancies after multiple myeloma, in particular hematologic malignancies. A retrospective cohort study was conducted in 3970 patients with newly diagnosed multiple myeloma from the registry of catastrophic illnesses between 1997 and 2009. A total of 15880 subjects without multiple myeloma were randomly selected as comparisons from the insured population, frequency-matched based on gender, age, and the date of diagnosis. The incidence of secondary malignancies was ascertained through cross-referencing with the National Cancer Registry System. The Cox proportional hazards model was used for analyses. The incidence of multiple myeloma in the insured population increased annually. The overall incidence of secondary malignancy was lower in the multiple myeloma cohort than in the comparison cohort (93.6 vs. 104.5 per 10,000 person-years, IRR = 0.90, 95% CI = 0.78-1.04). The incidence of hematologic malignancies was 11-fold greater for multiple myeloma patients (47.2 vs. 4.09 per 10,000 person-years) with an adjusted HR of 13.0 (95% CI = 7.79-21.6) compared with the comparison cohort. The relative risk of secondary malignancy was also strong for myeloid leukemia (21.2 vs. 1.36 per 10,000 person-years). Gender- and age-specific analysis for secondary hematologic malignancies showed that males and patients with multiple myeloma 60 years of age. In conclusion, patients with multiple myeloma, especially younger patients, are at a high risk of hematologic malignancies.

Original languageEnglish
Article numbere68041
JournalPLoS One
Volume8
Issue number7
DOIs
Publication statusPublished - Jul 2 2013

Fingerprint

myeloma
Multiple Myeloma
Taiwan
Hematologic Neoplasms
Population
Neoplasms
Insurance
incidence
Hazards
Incidence
Registries
Catastrophic Illness
myeloid leukemia
Myeloid Leukemia
Second Primary Neoplasms
gender
insurance
relative risk
cohort studies
Proportional Hazards Models

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients : A Taiwan Population-Based Study. / Tzeng, Huey En; Lin, Cheng Li; Tsai, Chun Hao; Tang, Chih Hsin; Hwang, Wen Li; Cheng, Ya Wen; Sung, Fung Chang; Chung, Chi Jung.

In: PLoS One, Vol. 8, No. 7, e68041, 02.07.2013.

Research output: Contribution to journalArticle

Tzeng, Huey En ; Lin, Cheng Li ; Tsai, Chun Hao ; Tang, Chih Hsin ; Hwang, Wen Li ; Cheng, Ya Wen ; Sung, Fung Chang ; Chung, Chi Jung. / Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients : A Taiwan Population-Based Study. In: PLoS One. 2013 ; Vol. 8, No. 7.
@article{610f9d0491fd4e5d9f1b908cf4a1849c,
title = "Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients: A Taiwan Population-Based Study",
abstract = "Studies involving second malignancies in patients with multiple myeloma are limited for the Asian population. Using data from population-based insurance claims, we assessed the risk of developing secondary malignancies after multiple myeloma, in particular hematologic malignancies. A retrospective cohort study was conducted in 3970 patients with newly diagnosed multiple myeloma from the registry of catastrophic illnesses between 1997 and 2009. A total of 15880 subjects without multiple myeloma were randomly selected as comparisons from the insured population, frequency-matched based on gender, age, and the date of diagnosis. The incidence of secondary malignancies was ascertained through cross-referencing with the National Cancer Registry System. The Cox proportional hazards model was used for analyses. The incidence of multiple myeloma in the insured population increased annually. The overall incidence of secondary malignancy was lower in the multiple myeloma cohort than in the comparison cohort (93.6 vs. 104.5 per 10,000 person-years, IRR = 0.90, 95{\%} CI = 0.78-1.04). The incidence of hematologic malignancies was 11-fold greater for multiple myeloma patients (47.2 vs. 4.09 per 10,000 person-years) with an adjusted HR of 13.0 (95{\%} CI = 7.79-21.6) compared with the comparison cohort. The relative risk of secondary malignancy was also strong for myeloid leukemia (21.2 vs. 1.36 per 10,000 person-years). Gender- and age-specific analysis for secondary hematologic malignancies showed that males and patients with multiple myeloma 60 years of age. In conclusion, patients with multiple myeloma, especially younger patients, are at a high risk of hematologic malignancies.",
author = "Tzeng, {Huey En} and Lin, {Cheng Li} and Tsai, {Chun Hao} and Tang, {Chih Hsin} and Hwang, {Wen Li} and Cheng, {Ya Wen} and Sung, {Fung Chang} and Chung, {Chi Jung}",
year = "2013",
month = "7",
day = "2",
doi = "10.1371/journal.pone.0068041",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients

T2 - A Taiwan Population-Based Study

AU - Tzeng, Huey En

AU - Lin, Cheng Li

AU - Tsai, Chun Hao

AU - Tang, Chih Hsin

AU - Hwang, Wen Li

AU - Cheng, Ya Wen

AU - Sung, Fung Chang

AU - Chung, Chi Jung

PY - 2013/7/2

Y1 - 2013/7/2

N2 - Studies involving second malignancies in patients with multiple myeloma are limited for the Asian population. Using data from population-based insurance claims, we assessed the risk of developing secondary malignancies after multiple myeloma, in particular hematologic malignancies. A retrospective cohort study was conducted in 3970 patients with newly diagnosed multiple myeloma from the registry of catastrophic illnesses between 1997 and 2009. A total of 15880 subjects without multiple myeloma were randomly selected as comparisons from the insured population, frequency-matched based on gender, age, and the date of diagnosis. The incidence of secondary malignancies was ascertained through cross-referencing with the National Cancer Registry System. The Cox proportional hazards model was used for analyses. The incidence of multiple myeloma in the insured population increased annually. The overall incidence of secondary malignancy was lower in the multiple myeloma cohort than in the comparison cohort (93.6 vs. 104.5 per 10,000 person-years, IRR = 0.90, 95% CI = 0.78-1.04). The incidence of hematologic malignancies was 11-fold greater for multiple myeloma patients (47.2 vs. 4.09 per 10,000 person-years) with an adjusted HR of 13.0 (95% CI = 7.79-21.6) compared with the comparison cohort. The relative risk of secondary malignancy was also strong for myeloid leukemia (21.2 vs. 1.36 per 10,000 person-years). Gender- and age-specific analysis for secondary hematologic malignancies showed that males and patients with multiple myeloma 60 years of age. In conclusion, patients with multiple myeloma, especially younger patients, are at a high risk of hematologic malignancies.

AB - Studies involving second malignancies in patients with multiple myeloma are limited for the Asian population. Using data from population-based insurance claims, we assessed the risk of developing secondary malignancies after multiple myeloma, in particular hematologic malignancies. A retrospective cohort study was conducted in 3970 patients with newly diagnosed multiple myeloma from the registry of catastrophic illnesses between 1997 and 2009. A total of 15880 subjects without multiple myeloma were randomly selected as comparisons from the insured population, frequency-matched based on gender, age, and the date of diagnosis. The incidence of secondary malignancies was ascertained through cross-referencing with the National Cancer Registry System. The Cox proportional hazards model was used for analyses. The incidence of multiple myeloma in the insured population increased annually. The overall incidence of secondary malignancy was lower in the multiple myeloma cohort than in the comparison cohort (93.6 vs. 104.5 per 10,000 person-years, IRR = 0.90, 95% CI = 0.78-1.04). The incidence of hematologic malignancies was 11-fold greater for multiple myeloma patients (47.2 vs. 4.09 per 10,000 person-years) with an adjusted HR of 13.0 (95% CI = 7.79-21.6) compared with the comparison cohort. The relative risk of secondary malignancy was also strong for myeloid leukemia (21.2 vs. 1.36 per 10,000 person-years). Gender- and age-specific analysis for secondary hematologic malignancies showed that males and patients with multiple myeloma 60 years of age. In conclusion, patients with multiple myeloma, especially younger patients, are at a high risk of hematologic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=84879768294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879768294&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0068041

DO - 10.1371/journal.pone.0068041

M3 - Article

C2 - 23844152

AN - SCOPUS:84879768294

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e68041

ER -